Exhibit 99.1
Company Contact
Mr. Y. Tristan Kuo
Chief Financial Officer
China Biologic Products, Inc.
Telephone: +86-538-6202206
Email: ir@chinabiologic.com
www.chinabiologic.com
FOR RELEASE ON AUGUST 9, 2011 AT 4:35 p.m. EDT (New York)
China Biologic Products Reports Second Quarter 2011 Results
TAI'AN, Shandong Province, China, August 9, 2011 – China Biologic Products, Inc. (NASDAQ: CBPO) (“China Biologic” or the “Company”), one of the leading plasma-based biopharmaceutical companies in the People’s Republic of China (“PRC”), today reported its results for the three months ended June 30, 2011.
Financial highlights for the second quarter 2011
- Total sales in US dollars increased 1.9% in the second quarter 2011 to $41.7 million from the second quarter 2010, with the benefit of 4.8% foreign exchange translation gain. Total sales denominated in RMB decreased 2.9% in the second quarter from the second quarter of last year.
- Gross profit decreased 8.5% to $29.2 million in the second quarter 2011 from the same period in 2010. The gross profit margin was 70.0% in the second quarter 2011 compared with 77.9% in the second quarter 2010.
- Income from operations decreased 24.3% to $17.2 million in the second quarter 2011 from the prior second quarter.
- GAAP Net income attributable to China Biologic increased 28.3% to $16.6 million or $0.28 per diluted share in the second quarter 2011 from the second quarter 2010.
- Excluding non-cash employee stock compensation, non-cash gain related to change in fair value of derivative liability, and interest on convertible notes, the non-GAAP adjusted net income attributable to China Biologic was $8.7 million or $0.33 per diluted share in the second quarter 2011, a 20.5% decrease from $11.0 million or $0.41 per diluted share in last year’s second quarter.
CEO Comments
Mr. Chao Ming Zhao, Chief Executive Officer of China Biologic, said, “We understand that investors have concerns about the unexpected closing of four of our plasma collection stations in Guizhou province that occurred on August 1, 2011 at the direction of the Guizhou Provincial government’s newly imposed plan and policy. These stations accounted for about 34.1% of our total raw plasma volume collected in 2010.”
“To mitigate the effects from the closing of the 4 plasma collection stations, we are working on alternative solutions and opportunities that include minimizing the write-off of already collected plasma from these 4 stations by performing all tests required by the 90-day quarantine rules, reallocating resources from the closed stations to maximize their utilization within the Company, and exploring new regions for new plasma stations.”
page 1
“In addition, we are adjusting our production plan and sales strategy to leverage the available resources to maximize profit as we respond to the changing market dynamics. For example, given the limited supply of raw plasma in the future, we will focus on supplying our products, which are critical and irreplaceable to health care, via direct sales to our best customers. We remain committed to accelerating our earnings growth in the future -- by focusing on our direct institutional sales, broadening our geographic reach, finding and creating new raw plasma sources, continuing to develop a strong new product pipeline, and considering possible prudent acquisitions, mergers and potential international collaborations.”
"Our sales, in terms of RMB, decreased slightly in the second quarter, mainly due to weaker product pricing in a more competitive market and lower revenue from high-value hyper-immune products due to unavailability of specific vaccinated plasma raw material. Additionally, we unified the labels and packaging of the products from our two subsidiaries so that our Taibang brand becomes our primary brand. It took us much longer to relabel and repackage the products than we expected, which resulted in delays in shipping and revenue recognition for IVIG products.”
“Given that some factors are still evolving and it remains uncertain how they will be resolved, we have revised our guidance based on the current available information. For that reason, we recommend an extra measure of caution in interpreting our revised guidance.”
“I assure you that we are working around the clock to recover from the unexpected loss of the 4 raw plasma collection stations in Guizhou. We plan to update you about our progress when we reach meaningful milestones.”
Results for the three months ended June 30, 2011
Our revenue increased by 1.9% to $41.7 million during the second quarter 2011 from $40.9 million for the same period in 2010. The foreign exchange translation contributed a 4.8% increase in sales, which translated into a 2.9% decrease in sales denominated in RMB. The revenue decrease in terms of RMB was primarily a result of the combined effect of the fluctuation on both price and volume of plasma based products. Due to increased market competition, most of the Company’s plasma products experienced general price decreases ranging from 4.2% to 16.2% .
Among all of products, only human immunoglobulin for intravenous injection (“IVIG”), which had an approximately 3.2% average selling price (“ASP”), increase as compared to the same quarter in 2010 year-over-year. Sales of Human Albumin remained the largest revenue contributor, accounted for 51.3% of the total sales. While experiencing approximately 4.2% ASP decline, sales volume of Human Albumin increased 18.3% year-over-year.
IVIG, the second largest revenue contributor which accounted for 38.6% of total sales, experienced an average year-over-year volume decrease of 2.7% in the second quarter of 2011.
Human Hepatitis B Immunoglobulin experienced the sharpest ASP decrease, down 16.2% compared to the same period of prior year, and contributed 4.5% of the total sales in the second quarter of 2011. The price decrease in human hepatitis B immunoglobulin products was mainly due to the Company’s participation in a public health program sponsored by PRC’s Ministry of Health benefiting migrant workers. The sales price for this public health program was lower than the normal retail price in order to benefit migrant workers.
Human tetanus immunoglobulin products experienced largest sales volume increase of 77.1%, with a 5.3% ASP decline, and contributed 4.7% of total sales in the second quarter of 2011. The significant volume variance of hyper-immune products year-over-year was attributable to the availability of specific vaccinated plasma and production lines.
page 2
Gross profit decreased $2.7 million or 8.5% to $29.2 million in the second quarter of 2011 from $31.8 million in the second quarter of 2010. Gross profit margin was 70.0% in the second quarter of 2011, as compared to the 77.9% for the same period in 2010. The decrease in gross profit margin was primarily attributable to the decrease in the ASP of most of products and increased cost of raw material plasma due to our efforts to increase plasma collection volume.
Total operating expenses in the second quarter of 2011 increased 31.3% to $11.9 million, as compared to $9.08 million in the second quarter of 2010. As a percentage of sales, total operating expenses increased to 28.6% in the second quarter of 2011, from 22.2% for the same period in 2010.
Selling expenses increased by $1.2 million, or 63.6%, to $3.0 million in the second quarter of 2011 from $1.9 million in the second quarter of 2010. Selling expenses as a percent of sales increased to 7.3% in the second quarter of 2011 from 4.5% for the same period in 2010. The increase in selling expenses was in line with our continuing effort to expand our customer base in hospital and inoculation centers throughout the PRC in a bid to counter the negative impact of the general price decreases of our products caused by heightened competitive pressures.
General and administrative expenses increased by $1.8 million, or 29.8%, to $7.7 million in the second quarter of 2011 from $5.9 million in the second quarter of 2010. General and administrative expenses as a percent of sales increased to 18.4% in the second quarter of 2011, from 14.4% in the same period of 2010. The increase in general and administrative expenses was primarily due to an increase in expenses related to payroll and employee benefits, as well as an increase of approximately $1.2 million in non-cash employee stock compensation expenses. The increase in payroll was mainly due to our efforts to enhance corporate governance with the addition of two directors during the first quarter of 2011, the addition of a new executive officer in December 2010, and the addition of our corporate offices in Beijing.
Research and development expenses decreased by $0.1 million, or 7.5%, to $1.2 million in the second quarter of 2011, from $1.3 million in the second quarter of 2010. As a percent of sales, research and development expenses were 2.9% and 3.2% in the second quarter of 2011 and 2010, respectively. The decrease in research and development expenses was primarily due to the decreased cost associated with the development of two new products, which we are waiting for the PRC’s State Food and Drug Administration (“SFDA”) approval. Due to the delay of SFDA approval process, we expect to receive the approval for these two new products in early 2012.
Income from operations decreased 24.3% to $17.2 million in the second quarter of 2011, as compared to $22.8 million in the second quarter of 2010. The operating income margin was 41.4% and 55.7% for the quarter ended June 30, 2011 and 2010, respectively.
For the quarter ended June 30, 2011 and 2010, we recognized a gain from the change in fair value of derivative liabilities in the amounts of $11.2 million and $2.3 million, respectively. The recognized gain from the change in the fair value of derivative liabilities in the second quarter of 2011 was mainly due to a decrease in the price of our common stock from $15.96 as of March 31, 2011 to $10.20 as of June 30, 2011.
Our provision for income taxes increased to $5.3 million in the second quarter of 2011, from $5.0 million in the second quarter of 2010, with effective income tax rate remained at 20%. The increase of income tax provision was mainly due to the increase in applicable income tax rate of Shandong Taibang and Guizhou Taibang from 15% to 25% for the three months ended June 30, 2011, compared with the same period in the prior year. Shandong Taibang is in the process of reapplying for the High and New Technology Enterprise qualification for an additional three years from 2011 to 2013. Guizhou Taibang, which was entitled to a preferential income tax rate of 15% under the previous 10-year Western Development Tax Concession, will apply for the Tax Concession in order to continue to enjoy the 15% preferential income tax rate from 2011 to 2020.
GAAP net income attributable to China Biologic in the second quarter of 2011 was $16.6 million, or $0.28 per diluted share, as compared to $12.9 million, or $0.41 per diluted share, in the same period of 2010. Non-GAAP adjusted net income was $8.7 million, or $0.33 per diluted share, in the second quarter of 2011, as compared to $11.0 million, or $0.41 per diluted share, in the second quarter of 2010. Non-GAAP adjusted net income and diluted earnings per share in the second quarter 2011 excluded an aggregate $11.2 million of gains, which are related to the change in the fair value of derivative liabilities, and added back $1.2 million of non-cash employee stock compensation expenses and $2.1 million of interest related to the convertible notes under the if-converted method. Please refer to the table at the end of this release for the reconciliation of our non-GAAP measures to the nearest comparable GAAP measures.
page 3
Six Months Results
For the first six months ended June 30, 2011, our sales increased 12.0% to $76.1 million as compared to $68.0 million for the same period last year. The foreign exchange translation contributed a 4.7% increase in sales, which translated into a 7.3% increase in sales denominated in RMB. The increase in sales during the 2011 period was primarily attributable to a general mix of increases in prices and volumes for certain of our plasma based products.
Gross profit for the first six months of 2011 was $54.3 million, increased 4.1% from $52.1 million in the same period in 2010. Gross profit margin for the first six months of 2011 was 71.3%, as compared to 76.7% for the same period in 2010. The decrease in gross profit margin was mainly due to the price decreases of certain of our products and increases in raw material costs.
Income from operations for the period was $31.8 million, down 11.8% from $36.0 million in the first six months of 2010. The decrease in income from operations was mainly due to a 96.0% increase in selling expenses and 39.2% increase in general and administrative expenses for the period as compared to the same period in 2010.
Net income for the first six months of 2011 was $30.5 million, down 11.6% from $34.5 million in the first six months of 2010. Fully diluted earnings per share were $0.53 for the first six months of 2011 as compared to $0.68 in the first six months of 2010. Excluding non-cash employee stock compensation expenses, change in the fair value of derivative liabilities and interest related to the convertible notes under the if-converted method, non-GAAP adjusted net income for the six months ended June 30, 2011 was $16.7 million, or $0.62 per diluted share, a decrease of 10.0% from non-GAAP net income of $18.6 million, or $0.70 per diluted share, for the six months ended June 30, 2010.
Financial Condition
As of June 30, 2011, the Company had $76.8 million in cash and cash equivalents, approximately $95.2 million in working capital, and a current ratio of 233.8% . Total shareholders’ equity as of June 30, 2011 was $181.6 million, as compared with $145.0 million at December 31, 2010.
Guidance and business outlook for 2011
China Biologic expects the revised total 2011 sales in the range of approximately $140 million to $145 million. The Company expects 2011 adjusted net income to be in the range of $28 million to $31 million, excluding any non-cash charge or gain related to change in the fair value of derivative liabilities, stock-based compensation expense, any adjustments in the U.S. federal income tax provision in 2011 related to the look-through exception for Subpart F income which expiring on December 31, 2011 and non-cash impairment losses associated, if any, with the closures of 4 plasma collection stations in Guizhou. The Company has provided the revised outlook based on the following factors:
| | (i) | The unexpected closure of 4 plasma collection stations in Guizhou, will limit our near-term future raw plasma supply. Additionally, the unexpected closure of a number of plasma collection stations in Guizhou may reduce China’s plasma supply and could amplify the supply and demand imbalance for plasma products in China. Therefore, we have revised our sales and production strategies to maintain as smooth a product supply as possible to our key customers in a longer term. |
| | | |
| | (ii) | The Company may have less imminent flexibility in reducing the expenses for previously planned and ongoing marketing and sales efforts (to expand its geographic markets, add new customers, and increase direct sales to institutional customers), and in minimizing the general and administrative expenses related to the 4 closed plasma collection stations. Therefore, we anticipate lower adjusted net income for 2011 despite the modest anticipated growth in sales in 2011. |
page 4
Conference callChina Biologic will host a dial-in conference call at 7:00 a.m. EDT (New York) on August 10, 2011, to discuss its results for the second quarter 2011. To participate in the conference call, please dial the appropriate number about 10 minutes prior to the scheduled conference call time:
The dial-in details for the live conference call are:
| U.S. toll-free number | 1 866 549 1292 |
| Mainland China toll-free number | 800 876 8626 |
| Hong Kong local access | 3005 2050 |
| International toll number | +852 3005 2050 |
| Participant pass code | 674 477# |
A telephone replay of the call will be available after the conclusion of the conference all through 7:00 a.m. EDT on August 17, 2011.
| The dial-in details for the telephone replay are: |
| |
| U.S. toll-free number | 1 866 753 0743 |
| Mainland China toll free number | 800 876 8594 |
| Hong Kong local access | 3005 2020 |
| International dial-in toll number | +852 3005 2020 |
| Replay pass code | 138 012# |
Use of non-GAAP financial measures
This news release contains non-GAAP financial measures that exclude non-cash compensation expenses related to options granted to employees and directors under the Company's 2008 Equity Incentive Plan and changes in the fair value of derivative liabilities, including warrants and derivative instruments (including the conversion option) embedded in the Company’s Senior Secured Convertible Notes (after adding back interest related to the convertible notes under the if-converted method). To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of this item in this release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of the adjustments to GAAP results appears in the table accompanying this news release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi’an Huitian Blood Products Co., Ltd., is one of the leading plasma-based biopharmaceutical companies in China.
page 5
The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company’s plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. Please see the Company’s website www.chinabiologic.com for additional information.
Safe harbor statement
This release may contain certain “forward-looking statements” relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein are “forward-looking statements,” including, among others, statements regarding: the Company’s financial and business outlook in 2011, the closure of the plasma collection centers in Guizhou, its expected effect on the Company’s financial performance, business operations and the industry, the Company’s ability and plan to seek alternative solutions and opportunities, the Company’s production plan, sales strategy and its ability to maximize profit and adapt to changing market, the ability of the Company to achieve its commercial objectives, the business strategy, plans, and objectives of the Company and its subsidiaries, including its ability to successfully implement its growth strategies, including its strategy to expand direct sales to hospitals and inoculation centers in order to boost future sales, and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including its potential inability to achieve the expected financial performance in 2011 and growth, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on the SEC website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Financial statements follow.
page 6
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
| | For the three months ended | | | For the six months ended | |
| | June 30, 2011 | | | June 30, 2010 | | | June 30, 2011 | | | June 30, 2010 | |
Sales | | | | | | | | | | | | |
External customers | $ | 41,664,996 | | $ | 40,580,807 | | $ | 76,060,234 | | $ | 67,442,329 | |
Related party | | 462 | | | 327,509 | | | 76,046 | | | 564,540 | |
Total sales | | 41,665,458 | | | 40,908,316 | | | 76,136,280 | | | 68,006,869 | |
| | | | | | | | | | | | |
Cost of sales | | | | | | | | | | | | |
External customers | | 12,512,359 | | | 9,012,168 | | | 21,789,563 | | | 15,811,022 | |
Related party | | 210 | | | 46,738 | | | 34,604 | | | 46,738 | |
Cost of sales | | 12,512,569 | | | 9,058,906 | | | 21,824,167 | | | 15,857,760 | |
| | | | | | | | | | | | |
Gross profit | | 29,152,889 | | | 31,849,410 | | | 54,312,113 | | | 52,149,109 | |
| | | | | | | | | | | | |
Operating expenses | | | | | | | | | | | | |
Selling expenses | | 3,038,143 | | | 1,856,881 | | | 5,488,056 | | | 2,799,789 | |
General and administrative expenses | | 7,665,306 | | | 5,905,950 | | | 15,129,447 | | | 10,868,202 | |
Research and development expenses | | 1,218,977 | | | 1,317,483 | | | 1,929,968 | | | 2,486,138 | |
| | | | | | | | | | | | |
Income from operations | | 17,230,463 | | | 22,769,096 | | | 31,764,642 | | | 35,994,980 | |
| | | | | | | | | | | | |
Other expenses / (income) | | | | | | | | | | | | |
Equity in income of equity method investee | | (463,688 | ) | | (157,114 | ) | | (734,082 | ) | | (345,655 | ) |
Change in fair value of derivative liabilities | | (11,175,384 | ) | | (2,270,829 | ) | | (12,197,249 | ) | | (6,104,406 | ) |
Interest expense | | 2,300,601 | | | 619,469 | | | 3,981,523 | | | 953,058 | |
Interest income | | (269,594 | ) | | (180,464 | ) | | (439,725 | ) | | (333,000 | ) |
Other expenses / (income), net | | 846,051 | | | 102,465 | | | 1,070,282 | | | (717,504 | ) |
Total other income, net | | (8,762,014 | ) | | (1,886,473 | ) | | (8,319,251 | ) | | (6,547,507 | ) |
| | | | | | | | | | | | |
Earnings before income tax expense | | 25,992,477 | | | 24,655,569 | | | 40,083,893 | | | 42,542,487 | |
| | | | | | | | | | | | |
Income tax expense | | 5,317,249 | | | 4,961,895 | | | 9,580,465 | | | 8,033,042 | |
| | | | | | | | | | | | |
Net income | | 20,675,228 | | | 19,693,674 | | | 30,503,428 | | | 34,509,445 | |
| | | | | | | | | | | | |
Less: Net income attributable to the noncontrolling interest | | 4,075,523 | | | 6,757,992 | | | 7,594,748 | | | 10,910,014 | |
| | | | | | | | | | | | |
Net income attributable to China Biologic Products, Inc. | $ | 16,599,705 | | $ | 12,935,682 | | $ | 22,908,680 | | $ | 23,599,431 | |
| | | | | | | | | | | | |
Earnings per share: | | | | | | | | | | | | |
Basic | $ | 0.67 | | $ | 0.55 | | $ | 0.94 | | $ | 1.01 | |
Diluted | $ | 0.28 | | $ | 0.41 | | $ | 0.53 | | $ | 0.68 | |
| | | | | | | | | | | | |
Weighted average shares used in computation: | | | | | | | | | | | | |
Basic | | 24,632,774 | | | 23,511,435 | | | 24,492,728 | | | 23,449,508 | |
Diluted | | 26,738,279 | | | 26,599,255 | | | 26,802,683 | | | 26,541,685 | |
page 7
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED BALANCE SHEETS
| | June 30, | | | December 31, | |
| | 2011 | | | 2010 | |
ASSETS | | | | | | |
Current Assets | | | | | | |
Cash and cash equivalents | $ | 76,841,679 | | $ | 64,941,368 | |
Accounts receivable, net of allowance for doubtful accounts | | 20,392,860 | | | 9,922,111 | |
Accounts receivable - a related party | | - | | | 212,611 | |
Inventories | | 62,598,637 | | | 52,300,447 | |
Other receivables | | 2,103,222 | | | 2,727,110 | |
Prepayments and prepaid expenses | | 2,044,279 | | | 855,338 | |
Deferred tax assets | | 2,401,806 | | | 1,860,753 | |
Total Current Assets | | 166,382,483 | | | 132,819,738 | |
| | | | | | |
Property, plant and equipment, net | | 39,932,006 | | | 39,511,731 | |
Intangible assets, net | | 13,124,987 | | | 14,559,020 | |
Land use rights, net | | 4,954,026 | | | 4,701,450 | |
Prepayments and deposits for property, plant and equipment | | 6,429,300 | | | 4,254,423 | |
Goodwill | | 18,129,811 | | | 17,778,231 | |
Equity method investment | | 8,183,215 | | | 7,297,201 | |
Total Assets | $ | 257,135,828 | | $ | 220,921,794 | |
| | | | | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | | |
Current Liabilities | | | | | | |
Short-term bank loans | $ | 18,564,000 | | $ | 3,034,000 | |
Accounts payable | | 5,593,488 | | | 4,392,772 | |
Due to related parties | | 3,262,995 | | | 3,192,140 | |
Other payables and accrued expenses | | 21,738,685 | | | 21,606,730 | |
Advance from customers | | 4,496,574 | | | 3,560,018 | |
Income tax payable | | 9,555,911 | | | 6,659,805 | |
Other taxes payable | | 2,759,165 | | | 2,146,868 | |
Convertible notes | | - | | | 1,196,233 | |
Derivative liabilities - embedded conversion option in convertible notes | | - | | | 14,561,661 | |
Derivative liabilities - warrants | | 5,188,004 | | | 11,095,592 | |
Total Current Liabilities | | 71,158,822 | | | 71,445,819 | |
Other payable | | 338,604 | | | 333,008 | |
Deferred tax liabilities | | 3,999,634 | | | 4,098,834 | |
Total Liabilities | | 75,497,060 | | | 75,877,661 | |
| | | | | | |
Stockholders’ Equity | | | | | | |
Common stock: par value $.0001; 100,000,000 shares authorized; 25,551,125 and 24,351,125 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively | | 2,555 | | | 2,435 | |
Additional paid-in capital | | 46,160,371 | | | 35,435,139 | |
Retained earnings | | 78,647,781 | | | 55,739,101 | |
Accumulated other comprehensive income | | 11,129,413 | | | 8,023,121 | |
Total stockholders’ equity attributable to China Biologic Products, Inc. | | 135,940,120 | | | 99,199,796 | |
| | | | | | |
Noncontrolling interest | | 45,698,648 | | | 45,844,337 | |
| | | | | | |
Total Equity | | 181,638,768 | | | 145,044,133 | |
| | | | | | |
Commitments and contingencies | | | | | | |
| | | | | | |
Total Liabilities and Equity | $ | 257,135,828 | | $ | 220,921,794 | |
page 8
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
| | For the six months ended | |
| | June 30, 2011 | | | June 30, 2010 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | | | | | | |
Net income | $ | 30,503,428 | | $ | 34,509,445 | |
Adjustments to reconcile net income to cash provided by operating activities: | | | | | | |
Depreciation | | 2,192,436 | | | 1,670,321 | |
Amortization | | 1,769,484 | | | 1,740,659 | |
Loss on sale of property, plant and equipment | | 133,218 | | | 3,020 | |
(Reversal) / provision for doubtful accounts, net | | (14,674 | ) | | 423,922 | |
Write-down of obsolete inventories | | 151,014 | | | 219,897 | |
Deferred tax benefit | | (677,477 | ) | | (311,476 | ) |
Stock compensation | | 2,418,287 | | | 617,841 | |
Change in fair value of derivative liabilities | | (12,197,249 | ) | | (6,104,406 | ) |
Amortization of deferred note issuance cost | | 91,945 | | | 171,667 | |
Amortization of discount on convertible notes | | 3,503,767 | | | 312,259 | |
Equity in income of equity method investee | | (734,082 | ) | | (345,655 | ) |
Change in operating assets and liabilities: | | | | | | |
Accounts receivable - third parties | | (10,150,102 | ) | | (3,861,953 | ) |
Accounts receivable - a related party | | 214,587 | | | (6,264 | ) |
Other receivables | | 27,582 | | | (95,231 | ) |
Inventories | | (9,319,703 | ) | | (6,351,255 | ) |
Prepayments and prepaid expenses | | (1,299,510 | ) | | (849,198 | ) |
Accounts payable | | 1,200,716 | | | (446,713 | ) |
Other payables and accrued expenses | | 378,573 | | | 1,252,134 | |
Accrued interest - noncontrolling interest shareholders | | - | | | (2,068,526 | ) |
Advance from customers | | 857,251 | | | 169,398 | |
Income tax payable | | 2,735,990 | | | (1,294,805 | ) |
Other taxes payable | | 563,983 | | | - | |
Net cash provided by operating activities | | 12,349,464 | | | 19,355,081 | |
| | | | | | |
CASH FLOWS FROM INVESTING ACTIVITIES: | | | | | | |
Acquisition of a subsidiary, net of cash acquired | | - | | | (4,022,288 | ) |
Purchase of property, plant and equipment | | (4,596,500 | ) | | (6,154,212 | ) |
Purchase of intangible assets and land use right | | (413,925 | ) | | (559,436 | ) |
Net cash used in investing activities | | (5,010,425 | ) | | (10,735,936 | ) |
page 9
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
UNAUDTIED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
| | For the six months ended | |
| | June 30, 2011 | | | June 30, 2010 | |
| | | | | | |
CASH FLOWS FROM FINANCING ACTIVITIES: | | | | | | |
Proceeds from warrants exercised | | - | | | 689,160 | |
Proceeds from stock option exercised | | 100,000 | | | - | |
Proceeds from short term bank loans | | 18,373,200 | | | 5,867,600 | |
Repayment of short term bank loans | | (3,062,200 | ) | | (4,449,295 | ) |
Acquisition of noncontrolling interest | | (7,635,000 | ) | | - | |
Repayment of noncontrolling interest shareholder loan | | - | | | (3,652,500 | ) |
Dividend paid by subsidiaries to noncontrolling interest shareholders | | (5,589,920 | ) | | (4,864,240 | ) |
Net cash used in / (provided by) financing activities | | 2,186,080 | | | (6,409,275 | ) |
| | | | | | |
EFFECTS OF EXCHANGE RATE CHANGE IN CASH | | 2,375,192 | | | 209,310 | |
| | | | | | |
NET INCREASE IN CASH | | 11,900,311 | | | 2,419,180 | |
| | | | | | |
Cash and cash equivalents, beginning of period | | 64,941,368 | | | 53,843,951 | |
| | | | | | |
Cash and cash equivalents, end of period | $ | 76,841,679 | | $ | 56,263,131 | |
| | | | | | |
Supplemental cash flow information | | | | | | |
Cash paid for income taxes | $ | 7,521,952 | | $ | 9,500,399 | |
Cash paid for interest expense (net of capitalized interest) | $ | 370,918 | | $ | 161,684 | |
Noncash investing and financing activities: | | | | | | |
Convertible notes conversion | $ | 12,972,000 | | $ | 2,498,957 | |
Reclassification of warrant liability to paid-in capital upon warrants conversion | $ | - | | $ | 1,747,765 | |
Utilization of prepayments and deposits to acquire intangible assets | $ | - | | $ | 440,070 | |
Utilization of prepayments and deposits to acquire property, plant and equipment | $ | 836,000 | | $ | 629,166 | |
page 10
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
FOR THE THREE MONTHS ENDED JUNE 30, 2011 AND 2010
| | Three months Ended | | | Three months Ended | |
| | June 30, 2011 | | | June 30, 2010 | |
Net Income (Loss) Diluted EPS | | Net Income | | | EPS | | | Net Income | | | EPS | |
Adjusted Net Income for diluted net income per share - Non GAAP | $ | 8,744,754 | | $ | 0.33 | | $ | 10,994,991 | | $ | 0.41 | |
Non-cash employee stock compensation | $ | (1,243,405 | ) | | | | $ | (45,948 | ) | | | |
Adjusted Net Income for diluted net income per share | $ | 7,501,349 | | $ | 0.28 | | $ | 10,949,043 | | $ | 0.41 | |
Interest on the Notes | $ | (2,077,028 | ) | | | | $ | (284,190 | ) | | | |
Gain from change in fair value of embedded conversion option in the Notes | $ | 5,781,624 | | | | | $ | 1,752,403 | | | | |
Gain from change in fair value of warrants | $ | 5,393,760 | | | | | $ | 518,426 | | | | |
Net Income attributable to controlling interest | $ | 16,599,705 | | | | | $ | 12,935,682 | | | | |
Weighted average number of Shares | | 26,738,279 | | | | | | 26,599,255 | | | | |
page 11
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
FOR THE SIX MONTHS ENDED JUNE 30, 2011 AND 2010
| | Six months Ended | | | Six months Ended | |
| | June 30, 2011 | | | June 30, 2010 | |
Net Income (Loss) Diluted EPS | | Net Income | | | EPS | | | Net Income | | | EPS | |
Adjusted Net Income for diluted net income per share - Non GAAP | $ | 16,709,885 | | $ | 0.62 | | $ | 18,569,177 | | $ | 0.70 | |
Non-cash employee stock compensation | $ | (2,418,287 | ) | | | | $ | (617,841 | ) | | | |
Adjusted Net Income for diluted net income per share | $ | 14,291,598 | | $ | 0.53 | | $ | 17,951,336 | | $ | 0.68 | |
Interest on the Notes | $ | (3,580,167 | ) | | | | $ | (456,311 | ) | | | |
Gain from change in fair value of embedded conversion option in the Notes | $ | 6,289,661 | | | | | $ | 3,809,745 | | | | |
Gain from change in fair value of warrants | $ | 5,907,588 | | | | | $ | 2,294,661 | | | | |
Net Income attributable to controlling interest | $ | 22,908,680 | | | | | $ | 23,599,431 | | | | |
Weighted average number of Shares | | 26,802,683 | | | | | | 26,541,685 | | | | |
page 12
